Skip to main content

Ophthalmology Deal Benchmarks 2026

Median Upfront
$522M
Range: $287M - $821M
Total Deal Value
$2.5B
Range: $1.6B - $3.3B
Royalty Rate
9.1% - 18.2%
Tiered up to 22.2%
Dev Milestones
$387M
Range: $262M - $499M
Model Your Deal

Market Analysis

Ophthalmology licensing in 2026 is driven by gene therapy for inherited retinal diseases, next-generation anti-VEGF biologics, and novel dry AMD therapies. Phase 2 gene therapy deals for retinal indications carry a median total deal value of $2.5B, with upfront payments ranging from $287M to $821M. The curative potential and orphan drug status of retinal gene therapies support premium deal structures.

Gene therapy deals in ophthalmology feature heavily back-loaded milestone structures. Development milestones average $387M, reflecting the manufacturing scale-up and long-term durability challenges unique to ocular gene delivery. Regulatory milestones add $484M, while commercial milestones of $1.1B reward the path to market in high-value rare disease populations.

Royalty rates for ophthalmology deals range from 9.1% to 18.2% at the base tier, with gene therapy programs supporting higher escalation tiers reaching 22.2%. Anti-VEGF biosimilar competition in wet AMD is compressing royalties for follow-on biologics, while truly differentiated approaches (port delivery, gene therapy-delivered anti-VEGF) maintain premium terms.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How are gene therapy deals structured in ophthalmology?
Gene therapy deals for retinal diseases average $2.5B total deal value at Phase 2, with $522M median upfronts. The one-time curative treatment model and orphan drug pricing support premium valuations, though manufacturing complexity and long-term durability data requirements shape milestone-heavy structures.
What deal trends are shaping wet AMD licensing?
Wet AMD licensing is being reshaped by biosimilar competition against ranibizumab and aflibercept, driving demand for differentiated next-generation anti-VEGF agents. Port delivery systems, bispecific anti-VEGF/ANG2 antibodies, and gene therapy-mediated anti-VEGF expression are commanding the highest deal premiums in the wet AMD space.
What are typical deal terms for retinal disease licensing?
Retinal disease licensing deals span a wide range depending on modality and indication rarity. Gene therapy for inherited retinal dystrophies commands the highest premiums with total deal values of $2.5B, while small molecule and biologic approaches for more common conditions carry comparatively lower valuations but larger commercial milestone potential.

Related Benchmarks

Gene Therapy Deals

View

Rare Disease Deal Overview

View

Phase 2 Deal Benchmarks

View

Preclinical Deal Benchmarks

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating